- DiaSorin reported its first-quarter adjusted EBITDA at €107 million, beating estimates of €105.3 million and reflecting a 10% year-over-year increase.
- The adjusted EBITDA margin remained steady at 34%, similar to the previous year.
- EBITDA was recorded at €106 million, marking a 10% rise from the previous year.
- EBIT came in at €73 million, achieving a 16% increase year-over-year.
- Revenue for the first quarter was €313 million, surpassing estimates of €310.5 million and showing an 8.3% increase from the prior year.
- Net income was €52 million, a 13% year-over-year growth, although slightly below the estimate of €53.8 million.
- The company reaffirms its guidance for the fiscal year 2025.
- Analyst recommendations for DiaSorin include 7 buy ratings, 10 hold ratings, and 1 sell rating.
A look at DiaSorin SpA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
DiaSorin SpA, a manufacturer of reagents for in vitro diagnostics, shows a promising long-term outlook based on its Smartkarma Smart Scores evaluation. With solid scores in Resilience and Momentum at 4, the company demonstrates strength in weathering challenges and maintaining positive market momentum. This suggests a stable and growing position in the industry. Additionally, DiaSorin SpA scores a respectable 3 in Growth, indicating potential for expanding its market presence and increasing revenues over time.
Despite receiving slightly lower scores in Value and Dividend at 2 each, DiaSorin SpA still presents a favorable overall outlook. The company’s focus on manufacturing diagnostic reagents positions it well in the healthcare sector, where demand for diagnostic solutions remains high. Investors may find DiaSorin SpA an attractive prospect for long-term growth and stability in the evolving diagnostic market landscape.
**Summary**: DiaSorin S.p.A. is a company that specializes in manufacturing reagents for in vitro diagnostics.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
